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Myeloid angiogenic cells (MAC) derive from hematopoietic stem/progenitor cells (HSPCs) that are mobilized from the bone
marrow. They home to sites of neovascularization and contribute to angiogenesis by production of paracrine factors. The
number and function of proangiogenic cells are impaired in patients with diabetes or cardiovascular diseases. Both conditions
can be accompanied by decreased levels of heme oxygenase-1 (HMOX1), cytoprotective, heme-degrading enzyme. Our study is
aimed at investigating whether precursors of myeloid angiogenic cells (PACs) treated with known pharmaceuticals would
produce media with better proangiogenic activity in vitro and if such media can be used to stimulate blood vessel growth
in vivo. We used G-CSF-mobilized CD34+ HSPCs, FACS-sorted from healthy donor peripheral blood mononuclear cells
(PBMCs). Sorted cells were predominantly CD133+. CD34+ cells after six days in culture were stimulated with atorvastatin
(AT), acetylsalicylic acid (ASA), sulforaphane (SR), resveratrol (RV), or metformin (Met) for 48 h. Conditioned media from
such cells were then used to stimulate human aortic endothelial cells (HAoECs) to enhance tube-like structure formation in a
Matrigel assay. The only stimulant that enhanced PAC paracrine angiogenic activity was atorvastatin, which also had ability to
stabilize endothelial tubes in vitro. On the other hand, the only one that induced heme oxygenase-1 expression was
sulforaphane, a known activator of a HMOX1 inducer—NRF2. None of the stimulants changed signiﬁcantly the levels of 30
cytokines and growth factors tested with the multiplex test. Then, we used atorvastatin-stimulated cells or conditioned media
from them in the Matrigel plug in vivo angiogenic assay. Neither AT alone in control media nor conditioned media nor AT-
stimulated cells aﬀected numbers of endothelial cells in the plug or plug’s vascularization. Concluding, high concentrations of
atorvastatin stabilize tubes and enhance the paracrine angiogenic activity of human PAC cells in vitro. However, the eﬀect was
not observed in vivo. Therefore, the use of conditioned media from atorvastatin-treated PAC is not a promising therapeutic
strategy to enhance angiogenesis.
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1. Introduction
Development of new blood vessels is necessary for the eﬀec-
tive tissue regeneration. Therefore, the mechanisms which
allow for the regulation of angiogenesis are of great impor-
tance. The process of neovascularization can be inﬂuenced
not only by the residual endothelial cells but also by the
circulating cells. Such myeloid angiogenic cells (MAC) [1]
of bone marrow origin were known as endothelial progenitor
cells (EPCs). EPCs are enriched in the population coexpres-
sing CD34, CD133, and KDR with a low or absent expression
of pan-hematopoietic marker CD45 [1]. In the cell culture,
they can bind Ulex europaeus lectin and acetylated low-
density lipoprotein (LDL) [2].
However, the features initially ascribed to endothelial
progenitor cells, i.e., phenotype, expression of endothelial
markers, and ability to form tube-like structures on Matrigel,
can be mimicked by blood monocytes [3]. Cells previously
known as endothelial progenitor cells are considered now
to be rather myeloid angiogenic cells than endothelial precur-
sors [4]. Endothelial progenitors should be devoid of hema-
topoietic markers and able to form vessels both in vitro and
in vivo. This change not only is of nomenclature signiﬁcance
but also indicates for the diﬀerent mechanisms of action, nec-
essary to be investigated for the better translational applica-
tion [5]. In our study, we worked on cells derived from the
CD34+ hematopoietic stem and progenitor cells, enriched
with CD133+ population, and used culture media promoting
growth of hematopoietic progenitors. Therefore, the cells we
used should be considered as hematopoietic precursors of
myeloid angiogenic cells and are referred as PACs. One
may speculate that more mature MAC would have better
paracrine proangiogenic activity than PAC. However, we
decided to use PAC over MAC based on our pilot study, in
which media promoting the growth of hematopoietic pro-
genitors gave us the highest yield of cells out of all tested
serum-free compositions.
Importantly, conditionedmedia fromMAC better induce
endothelial cell migration than those from human umbilical
vein endothelial cells (HUVECs) [6]. HUVEC cells treated
with the MAC-conditioned media upregulated antioxidant
genes coding for catalase, copper/zinc superoxide dismutase,
and manganese superoxide dismutase and were more resis-
tant to oxidative stress and apoptosis [7]. Moreover, MAC
produce proangiogenic microvesicles, which improve vascu-
larization of pancreatic islets [8] and protect kidneys from
ischemia-reperfusion injury [9]. Microvesicles from pheno-
typical EPC enhance vascularization in ischemic hind limbs
in an animal model [10]. Microvesicles derived from pheno-
typical EPC can also induce angiogenic program in endothe-
lial cells with the transfer of mRNA encoding for transcripts
involved in the PI3K/Akt pathway [11]. Media from MAC
or EPC potentially could be used for regenerative therapy.
Therefore, we aimed to evaluate if active compounds of med-
icines, or conditioned media from human peripheral blood
PAC stimulated with known pharmaceuticals, especially sta-
tins, could improve the angiogenesis both in vitro and in vivo.
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase—an enzyme that con-
trols the production of cholesterol. Therefore, statins are a
treatment of choice for lowering the cholesterol levels and
normalization of the high-density lipoprotein (HDL)/LDL
ratio. Apart from their inﬂuence on the cholesterol synthesis,
statins can also aﬀect the biology of both endothelial cells and
circulating proangiogenic cells. Statins enhance mobilization
of proangiogenic cells from the bone marrow [12] via the
PI3K/Akt pathway [13]. The positive eﬀect of statins on the
mobilization of proangiogenic cells was observed as well in
the diabetic patients with atherosclerotic vascular disease
[14], acute coronary syndromes, congestive heart failure,
hypertension, hypercholesterolemia, and vasoplastic anae-
mia (reviewed in [15]). Longer administration of statins,
i.e., longer than three months, could lead to the decrease in
numbers of circulating proangiogenic cells [16]. Atorvastatin
increased the proangiogenic cell proliferation and reduced
their senescence [17] and levels of age-related reactive oxy-
gen species [18]. Furthermore, proangiogenic cells pretreated
with statins were more resistant to apoptosis caused by oxi-
dized LDLs (oxLDLs) [19] and homocysteine [20]. Stimula-
tion of peripheral blood mononuclear cells with simvastatin
enhanced the expression of endothelial markers and produc-
tion of proangiogenic interleukin (IL) 8 [21], which seemed
to be one of the most critical EPC-derived paracrine mito-
gens for the mature endothelium [22]. Therefore, our objec-
tive was to investigate if PAC stimulated with high doses of
atorvastatin change the proﬁle of secreted growth factors
and immune modulators.
Finally, statins can induce expression of cytoprotective
and proangiogenic heme oxygenase-1 via the ERK/p38
MAPK/PKG [23], C/EBPβ, and AP-1 [24] in murine macro-
phages. The eﬀect of statins on the heme oxygenase-1 expres-
sion in circulating CD34+ HSPCs remains so far unknown.
Heme oxygenase-1 (encoded by the HMOX1 gene) is an
enzyme degrading heme to carbon monoxide (CO), biliver-
din, and Fe2+ ions.
Importantly, the polymorphism of theHMOX1 gene pro-
moter aﬀects the expression of heme oxygenase-1 in humans.
Our team has shown that the long promoter alleles (with
more GT repeats) result in the lower HMOX1 expression
[25]. Endothelial cells isolated from the people with the long
promoter are more sensitive to oxidative stress and show
lower proliferation response to VEGF than cells isolated from
the people with short, more active, promoter alleles [25].
Apart from its enzymatic activity, heme oxygenase-1
inﬂuences cell survival, resistance to the oxidative stress,
and angiogenesis [26]. We have recently shown that MAC
isolated from the bone marrow of Hmox1 knockout mice
present impaired proliferation, migration, and formation of
capillaries [27]. Accordingly, in human and mouse mature
endothelial cells, heme oxygenase-1 was necessary for the
SDF-1-induced migration [28].
Therefore, our last aim was to elucidate the relation
between atorvastatin and heme oxygenase-1 in guiding para-
crine activity of human PAC.
Circulating proangiogenic cells, since their discovery by
Asahara et al. in 1997 [2], have been an attractive subject of
many research and clinical trials. Importantly, such cells
can be sources of growth factors and immune modulations,
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which can altogether improve the tissue regeneration. The
strategy based on secretome would be attractive for regen-
erative medicine, since it would not depend on histocom-
patibility of cells but only on levels of factors they
produce. Therefore, this study is aimed at assessing both
in vitro and in vivo whether human PAC can be stimulated
with atorvastatin to produce conditioned media with
enhanced proangiogenic activity.
2. Materials and Methods
2.1. Isolation of Human Peripheral Blood CD34+. Human
peripheral blood CD34+ cells were isolated from peripheral
blood mononuclear cells (PBMCs) obtained from a healthy
volunteer, who was treated for ﬁve days with G-CSF (2 injec-
tions of 480 μg of G-CSF per day). The research complied
with the Declaration of Helsinki and was approved by
the local ethics committee. The donor provided written
informed consent for the study. PBMCs were obtained
with apheresis using a COBE® Spectra Apheresis System
in the Clinics of Hematology, Jagiellonian University Medical
College, Kraków, Poland. Remaining erythrocytes were
removed by centrifugation on the Ficoll Plus gradient (17-
1440-02, GE Healthcare). PBMCs were then aliquoted and
frozen in either CryoStor CS10 freezing medium (#07930,
Stem Cell Technologies) or PBS with 50% FBS and 10%
DMSO (DMS666, BioShop).
When necessary, aliquots of PBMC were thawed, and
cells were washed with PBS and treated for 30 minutes with
25 μg/mL DNase I (#10104159001, Roche) in PBS (#21-
030-CVR, Corning) with 5.0 μmol/L Mg2+ in order to pre-
vent cell clumping. Then, the cells were stained for 25
minutes with an anti-human CD34-FITC antibody (1 : 25,
#555821, clone 581, BD Pharmingen) and 10 minutes with
2 μg/mL 7-AAD (#559925, BD Pharmingen) at 4°C. Stained
cells were washed with 3mL of PBS, resuspended in the
AutoMACS Running Buﬀer (#130-091-221, Miltenyi Biotec),
and ﬁltered with a 40 μm cell strainer (CLS431750-50EA,
Corning). CD34+7AAD- cells were sorted on a Beckman
Coulter MoFlo XDP FACS sorter (Figure 1(a)).
2.2. Cell Culture. Cells were cultured in U-shaped, nonadher-
ent 96-well plates (150μL, 5 0 × 103 per well) in StemSpan-
ACF medium (#09855, Stem Cell Technologies) supple-
mented with 20% BIT9500 serum replacement (#9500,
Stem Cell Technologies), CC100 (#02690, Stem Cell Tech-
nologies) mix of cytokines, 50 ng/mL VEGF (#AF-100-20,
PeproTech), and penicillin with streptomycin (P4333-
100ML, Sigma Aldrich). Compositions of other tested media
are shown in Supplementary Table 1. After 48 hours, 50 μL of
fresh medium was added; then, 50 μL of medium was
changed every other day. On day 6 of culture, cells were
stimulated with 7.5, 15, or 30 μmol/L atorvastatin (#3776,
Tocris), 7.5, 15, or 30μmol/L resveratrol (R5010-100MG,
Sigma Aldrich), 125, 250, or 500μmol/L acetylsalicylic acid
(A5376-100G, Sigma Aldrich), 2.5, 5.0, or 10μmol/L
sulforaphane (S441-5MG, Sigma Aldrich), or 1.25, 2.5, or
5.0mmol/L metformin (#317240-5MG, Sigma Aldrich).
Conditioned media were collected after 48 hours. The
controls, nonconditioned media, contained the same
concentrations of stimulants and were kept for 48 hours in
a cell culture incubator in the same conditions as
stimulated cells. Wash-out conditioned media were
collected from stimulated cells after washing with PBS and
reseeding on 96-well plates in the complete fresh medium.
DMSO, which was used to dissolve all stimulants, was
added to the control wells.
2.3. Phenotyping of Human Peripheral Blood Mononuclear
Cells. Human peripheral blood mononuclear cells from the
G-CSF-treated healthy volunteer were stained in an
AutoMACS Running Buﬀer in 4°C with the following anti-
bodies: cocktail of antibodies for hematopoietic lineage
markers (Lin) (anti-CD2-FITC (#555326, clone RPA2.10),
anti-CD3-FITC (#555332, clone UCHT1), anti-CD14-FITC
(#345784, clone M5E2), anti-CD16-FITC (#555406, clone
3G8), anti-CD19-FITC (#555412, clone HIB19), anti-
CD24-FITC (#555427, clone ML5), anti-CD56-FITC
(#345811, clone NCAM16.2), anti-CD66b-FITC (#555724,
clone G10F5), and anti-CD235a-FITC (#559943, clone GA-
R2(HIR2), all 1 : 200) all from BD Pharmingen), anti-
CD45-APC-Cy7 (#304014, clone 2D1, BD Biosciences,
1 : 50), anti-CD34-APC or anti-CD34-FITC (#555824,
#555821, clone 581, BD Pharmingen, 1 : 50), anti-CD133-
PE (#130-080-801, clone AC133, Miltenyi Biotec, 1 : 50),
anti-CD105-PE (#323206, clone 43A3, BioLegend, 1 : 50),
anti-CD90-APC (#559869, clone 5E10, BioLegend), anti-
CD181-APC (#551080, clone 5A12, BD Pharmingen), anti-
CD184(CXCR4)-APC (#555976, clone 12G5, BioLegend,
1 : 50), anti-CD11b-APC (#101211, clone M1/70, BioLegend,
1 : 50), and 10 μg/mL Hoechst 33342 (B2261-25MG, Sigma
Aldrich). Stained cells were then analyzed on a BD LSR II
ﬂow cytometer using BD FACS Diva software (Becton Dick-
inson). Controls for gating are shown in Supplementary
Figure 1.
2.4. Matrigel Assay. The assaywas performed in 96-well plates
with 50μL of growth factor reducedMatrigel (#356231, Corn-
ing) per well. 1 0 × 104 HAoEC cells were seeded in each well
in 50μL of EBM-2 medium (#00190860, Lonza) supple-
mented with 2% FBS. After 30 minutes, 50μL of conditioned
medium was added to the cells. Nonconditioned media with
the same stimulants were used as controls. EBM-2 with
2% FBS was used as a negative control, whereas EGM-2
CM was a positive one. Pictures of formed structures were
taken after 16 hours and then analyzed with ImageJ software,
with an Angiogenesis Analyzer (source: http://image.bio
.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ
&artpage=4-7#outil_sommaire_4).
2.5. Fibrin Bead Assay. Human aortic endothelial cells were
seeded on Cytodex 3 microcarrier beads (#17-0485-03, GE
Healthcare Life Sciences) and incubated for 6-8 h to allow
the cells to attach. After 24 h of incubation in T25 ﬂasks,
beads with cells were resuspended in EBM-2 basal medium
with 2mg/mL ﬁbrinogen (F3879-100MG, Sigma Aldrich),
mixed with thrombin (15 μL of 50U/mL per well, T9326-
150UN, Sigma Aldrich), and seeded on 24-well plates. After
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Figure 1: Continued.
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Figure 1: Gating for sorting of CD34+7AAD- cells. CD34+7AAD- cells constituted 1.6-2% of cryostored PBMCs (a); CD34+ cells constituted
1.53% of fresh isolated PBMCs. In majority, they were positive for CD133 (68.8%) and negative for most of tested markers: CD11b, CD14,
CD16, CXCR4, and CD105, and 21.9% of them were positive for CD90. Phenotyping of obtained PBMCs was assessed with ﬂow
cytometry. Cells (b), Hoechst+ nucleated cells (c), singlets (d), Lin- cells (e), CD34+ or CD34+CD133+ cells within Lin-Hoe+ cells (f),
CD34+ cells within nucleated cells (g), CXCR4 vs. CD133 within CD34+ cells (h), CD11b vs. CD133 within CD34+ cells (i), CD181 vs.
CD133 within CD34+ cells (j), CD16 vs. CD14 within CD34+ cells (k), and CD90 vs. CD105 within CD34+ cells (l).
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brief polymerization, control media or media collected
from cells treated with 30μM atorvastatin were added at
the top of a ﬁbrin clot. Pictures of the beads were taken
after 72 hours of incubation using a Nikon Eclipse TE
2000-U microscope.
2.6. Matrigel Plug Assay In Vivo. All procedures involving the
use of animals were performed according to approved guide-
lines. Mice were maintained under the speciﬁc pathogen-free
conditions, in individually ventilated cages, with full access to
food and water. All animal experiments were approved by the
Local Ethical Committee for Animal Research at the Jagiello-
nian University (no. 114/2014). Experiments in vivo were
done using Foxn1nu mice. Brieﬂy, conditioned media from
PACs stimulated with 30 μmol/L atorvastatin or DMSO,
nonconditioned media, or wash-out media were mixed with
growth factor reduced Matrigel (#356231, Corning, lot
4097006 used for all plugs) 1 : 1.5. Then, 250 μL of Matrigel
with media was injected subcutaneously to mice on both
ﬂanks of the abdomen. Plugs with Matrigel mixed with PBS
in the same ratio served as the negative control. Additionally,
PACs, stimulated with either DMSO or 30μmol/L atorva-
statin for 48 hours, were also mixed with Matrigel diluted
with PBS 1.5 : 1, (2 5 × 105 cells in each plug) and injected
subcutaneously to test the activity of cells.
Vascularization of the plug was assessed with a
VEVO2100 ultrasonography system (VisualSonics) using
the 3D and PowerDoppler Modes 7 days after injection.
After two weeks, mice were sacriﬁced, and plugs were
excised, then cut into small pieces and digested with the
enzyme mix: 3U/mL Liberase™ (#5410127001, Roche),
25 μg/mL hyaluronidase (H4272-30MG, Sigma Aldrich),
25 μg/mL DNase (#10104159001, Roche), and 3 IU/mL dis-
pase (#17105041, Gibco) for 1 hour at 37°C. The reaction
was stopped with FBS. Cells were then ﬁltered through a
70 μm cell strainer (CLS431751-50EA, Corning), centri-
fuged (600 g, 10 minutes), and stained in 2% FBS in PBS
at 4°C for 20 minutes with the following antibodies: anti-
mouse CD31 PE (#553373, clone MEC13.3, BD Biosciences,
1μg/mL), anti-mouse CD45 APC (#559864, clone 30F-11,
BD Biosciences, 1μg/mL), and 0.5μg/mL DAPI (D9542-
10MG, Sigma Aldrich). Stained cells were then analyzed
on BD LSRFortessa. Obtained data were then analyzed with
FlowJo software.
2.7. Multiplex Immunoassays. The concentration of factors
produced by PACs was measured with the Cytokine
Human 30-Plex Panel (LHC6003M, Invitrogen) on the
Luminex FLEXMAP 3D platform according to the manu-
facturer’s protocol.
2.8. NanoSight Analysis. Average size, mode size, and num-
ber of microvesicles released from PACs stimulated with
DMSO or 30 μmol/L atorvastatin for 48 hours were analyzed
with a LM10HS microscope equipped with the LM14 488nm
laser module (Malvern Instruments Ltd., Malvern, UK) at the
Department of Clinical Immunology, Institute of Pediatrics,
Jagiellonian University Medical College, Kraków, Poland.
Collected conditioned media were spun down at 1000 g for
10 minutes and then diluted 200x in 0.2μm-ﬁltered PBS
before the measurement.
2.9. Transduction of CD34+ Cells. To increase the eﬃciency of
transduction, CD34+ cells were transduced in U-shaped 96-
well plates using spinofection. Overexpression of heme
oxygenase-1 was achieved with lentiviral vectors LeGO-
HMOX1-iG2 encoding HMOX1 and GFP. LeGO-iG2 vector
encoding GFP only was used as a control. Silencing of
HMOX1 was done with lentiviral vectors pGFP-C-shLenti
from OriGene. We tested 4 diﬀerent sequences of shRNA
and used vectors with scramble shRNA sequence as a control.
Brieﬂy, vectors were added to cells, which were subsequently
spun in their culture plates for 1 hour at 800 g. 48 hours later,
cells were washed and stimulated with DMSO or atorva-
statin. Additionally, 10 μmol/L tin protoporphyrin IX (SnPP)
was used as the HMOX1 inhibitor and 10μmol/L copper
protoporphyrin IX (CoPP) as the HMOX1 activator
(#Sn749-9, #Co654-9, both from Frontier Scientiﬁc).
2.10. Gene Expression Analysis. Total RNA was isolated with
phenol-chloroform extraction and reverse-transcribed with
the NCode™ VILO™ miRNA cDNA synthesis kit (A11193-
050, Invitrogen). The expression of genes was assessed with
quantitative real-time PCR (qRT-PCR), which was per-
formed in the StepOnePlus system (Applied Biosystems, Fos-
ter City, CA, USA) with the speciﬁc primers (HMOX1 For: 5′
-TCTATATTTAGGGCCGCCAG-3′, Rev: 5′-CAGCTC
CTGCAACTCCTCAAA-3′; ACTB For: 5′-AAGGGACTT
CCTGTAACAACGCA-3′, Rev: 5′-CTGGAACGGTGAAG
GTGACA-3′) cDNA and SYBR® Green JumpStart™ Taq
ReadyMix™ (S4438-500RXN, Sigma Aldrich) according to
the manufacturer’s protocol.
2.11. Statistical Analysis. Statistical analysis of the data was
performed with GraphPad Prism 7 software. Results are
expressed as the mean ± SD. Data obtained in in vitro exper-
iments were analyzed with a Student t-test when two groups
of samples were used. In other cases, we used one-way or
two-way ANOVA with Bonferroni post hoc test. The kind
of statistical test applied to analyze given sets of data is pro-
vided in the description of ﬁgures.
3. Results
3.1. Obtained PBMCs Contained High Proportion of CD34+
HSPCs. Paracrine angiogenic activity is considered as a criti-
cal role played by myeloid angiogenic cells in the regulation
of blood vessel formation. Conditioned media from such cells
can be used to stimulate blood vessel growth and enhance tis-
sue regeneration. We decided to evaluate if widely used drugs
atorvastatin, acetylsalicylic acid, metformin and also sulfo-
raphane and resveratrol are able to improve in vitro the
proangiogenic activity of human peripheral blood CD34+-
derived cells, which are precursors of MAC.
First, we checked the phenotype of cells that were
obtained with apheresis from a healthy donor who was
administered with G-CSF for 5 consecutive days. The pheno-
type of CD34+ cells was assessed within the population of
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single, nucleated cells from PBMC isolated from a healthy
donor (Figures 1(b)–1(d)). Within Lin-CD45+ cells
(Figure 1(e)), CD34+ cells constituted 49.4% of cells and
68.8% of them expressed CD133 (Figure 1(f)). Only a small
fraction of CD45dimCD34+ (Figure 1(g)) expressed CXCR4
(Figure 1(h)), CD11b (Figure 1(i)), and CD181 (Figure 1(j)),
which is a receptor for CXCL1 (IL-8), CD14, and CD16
(Figure 1(k)), and 21.9% of them expressed CD90, while
CD105 was virtually absent (Figure 1(l)). The highest yield
of CD34+ cells in culture was obtained in medium based on
StemSpan-ACF, and therefore, we used it for all consecutive
experiments (Supplementary Figure 2). To sum up, we
obtained a large number of human CD34+ cells, which
expressed CD133 and lacked lineage markers.
3.2. Media from Atorvastatin-Treated Cells Increase Tube
Formation on Matrigel. Treatment of PAC with atorvastatin
enhanced their paracrine angiogenic activity. HAoEC cells
were treated with conditioned media harvested from cells
stimulated for 48 h with atorvastatin, acetylsalicylic acid, res-
veratrol, sulforaphane, or metformin. Of note, conditioned
media contained the stimulants as well. Therefore, to distin-
guish the angiogenic activity of factors released by stimulated
cells from the eﬀect of stimulants alone, we used noncondi-
tioned media as controls. Nonconditioned media contained
the same concentrations of stimulants and were incubated
for the same period in the cell culture incubator as condi-
tioned media but without cells.
HAoEC cells used in the Matrigel assay in vitro formed
tube-like structures (Figure 2(a)). First of all, conditioned
media enhanced the tube formation in comparison to non-
conditioned ones. However, tube-like structures formed by
HAoEC cells stimulated with media from atorvastatin-
treated PAC were characterized by a higher number of
meshes, junctions, and segments (Figures 2(b)–2(d)). We
did not observe such an eﬀect in the case of other stimulants:
resveratrol, acetylsalicylic acid, sulforaphane, or metformin
(Supplementary Figure 3A-C). Interestingly, atorvastatin
in nonconditioned media in all tested concentrations also
improved the stability of tube-like structures formed by
HAoEC cells (Figures 2(b)–2(d)). Therefore, the overall
proangiogenic activity of conditioned media is rather an
additive eﬀect of both atorvastatin and factors produced
by PAC.
Then, we used the ﬁbrin bead assay, which allows asses-
sing the formation of 3D blood vessels with a lumen
(Figure 2(e)). We did not observe any diﬀerences in the num-
ber of sprouts (Figure 2(f)) or the average length of sprouts
(Figure 2(g)) formed by HAoEC cells stimulated with condi-
tioned media from atorvastatin-treated PAC in comparison
to control media. Therefore, while the media from PAC stim-
ulated with atorvastatin might have increased the prolifera-
tion of HAoEC cells, they seem not to aﬀect the formation
of the blood vessel.
3.3. Media from Atorvastatin-Treated CD34+ Cells Do Not
Enhance Angiogenesis In Vivo. Then, the paracrine angio-
genic activity of PAC stimulated with 30 μmol/L atorvastatin,
the highest dose used in vitro which showed a proangiogenic
eﬀect, was tested in the Matrigel plug assay in vivo. Similar to
in vitro experiments, we used conditioned media from PAC
treated with atorvastatin or nonconditioned media contain-
ing 30μmol/L atorvastatin and incubated in a cell culture
incubator for the same period without cells. Additionally,
we tested whether the paracrine angiogenic activity can be
maintained in atorvastatin-treated cells after wash-out of
the stimulant. Therefore, we harvested media from cells stim-
ulated with atorvastatin for 48 hours, which were then
washed and reseeded in growth medium for additional 48
hours. Media were mixed with growth factor reduced
Matrigel and injected subcutaneously to Foxn1nu mice to
form spherical plugs. Finally, to test the inﬂuence of the
CD34+-derived cells themselves, we mixed atorvastatin-
treated or control cells with Matrigel and injected them
subcutaneously into nude mice.
Angiogenic response to the media or cells was tested
with 3D ultrasound imaging of blood ﬂow in subcutaneous
plugs (Figure 3(a)) and ﬂow cytometry (Figure 3(b)). Plugs
with the control, nonconditioned media, conditioned
media, or conditioned media after the wash-out of atorva-
statin showed similar vascularization to the control ones with
vehicle only (Figures 3(b) and 3(c)). Numbers of inﬁltrating
CD45+ immune cells as well as CD45-CD31+ host endothelial
cells were similar in all groups (Figures 3(d) and 3(e)).
Similarly, neither control PAC nor PAC stimulated with
atorvastatin induced changes of plug vascularization or inﬁl-
tration with CD45+ or CD45-CD34+ cells (Figures 3(e)–3(g)).
Therefore, we concluded that the proangiogenic eﬀect of
conditioned media or PAC is too weak to be observed in
the Matrigel plug assay. Furthermore, in none of the condi-
tions tested, we have observed any changes in the local
inﬂammation in subcutaneous plugs in mice. One has to
notice, however, that the experiment was performed in
immunocompromised nude mice to avoid the immune reac-
tion to human antigens, and the conditioned media were
more diluted in in vivo experiments than in the Matrigel
assay in vitro.
3.4. Atorvastatin Does Not Change Levels of Growth Factors
and Mediators of Inﬂammation Produced by CD34+ Cells.
In order to further elucidate the paracrine activity of stim-
ulated PAC, observed in vitro, we tested concentration of
30 human growth factors and mediators of inﬂammation
in conditioned media from PAC stimulated with 7.5, 15,
or 30 μmol/L atorvastatin. Only IL-8 seemed to increase
upon stimulation with atorvastatin (Figure 4(a), Supple-
mentary Figure 4). However, it was not reproduced in
further experiments, even when cells were stimulated for a
more extended period, up to 144 hours (Figure 4(b),
Supplementary Figure 5). Since microvesicles may mediate
the proangiogenic eﬀect of circulating cells, we assessed the
mean particle number, mode, and mean particle sizes using
the nanoparticle tracking analysis. None of the parameters
tested was aﬀected by atorvastatin (Figures 4(c)–4(e)).
3.5. Atorvastatin Does Not Aﬀect the HMOX1 Expression in
CD34+ Cells. Finally, we assessed whether stimulation with
atorvastatin could aﬀect the expression of heme oxygenase-
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Figure 2: Continued.
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1, a known proangiogenic factor, which was crucial for the
paracrine angiogenic activity of mouse PAC cells [27]. The
only stimulant that enhanced HMOX1 expression in PAC
was sulforaphane, a known inductor of Nrf2 transcription
factor activity (Figure 5(a)). However, sulforaphane did
not aﬀect the paracrine angiogenic activity of the tested
population of PAC (Supplementary Figure 3). On the
other hand, atorvastatin, which increased PAC paracrine
angiogenic activity, did not change HMOX1 transcript
levels (Figure 5(a)). Furthermore, neither overexpression of
HMOX1 with lentiviral vectors nor HMOX1 silencing with
shRNA aﬀected the paracrine proangiogenic activity of
PAC (Figure 5(b)). HAoECs treated with media from PAC
with silenced HMOX1 and stimulated with atorvastatin
formed a similar number of junctions (Figure 5(c)). Last
but not least, neither chemical activation nor inhibition of
HMOX1 activity aﬀected the angiogenic activity of media
from PAC (Figure 5(d)). Therefore, we conclude that in
PAC, HMOX1 is not vital for the regulation of their
paracrine proangiogenic activity.
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Figure 2: Conditionedmedia from PAC stimulated with atorvastatin enhance the angiogenesis in the 2DMatrigel test but not in the 3D ﬁbrin
bead assay. HAoEC cells stimulated for 16 hours with conditioned media from PAC stimulated with atorvastatin or control, nonconditioned
media with atorvastatin (a); number of junctions, ∗p < 0 05 vs. nonconditioned, $$p < 0 01 vs. DMSO, conditioned (b); number of meshes,
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4. Discussion
The main ﬁnding of the study is that conditioned media from
human peripheral blood PAC-stimulated and atorvastatin
have additive proangiogenic activity in vitro in the Matrigel
assay but not in vivo in the subcutaneous Matrigel plug
model. The eﬀect in vitro was not mediated by heme
oxygenase-1 since the HMOX1 expression level was not
aﬀected by atorvastatin. On the other hand, increased expres-
sion ofHMOX1 induced in sulforaphane-treated cells did not
lead to any changes in paracrine proangiogenic activity.
Interestingly, conditioned media from C2C12 myoblast cells
overexpressing heme oxygenase-1 had higher proangiogenic
activity in vivo in ischemic hind limbs of db/db diabetic mice
[29]. Media from the latter cells were devoid of antiangio-
genic PEDF and BGN, which were present in media from
control cells, and contained more proangiogenic PPlase A,
MIF, haptoglobin, and galectin-1 [29].
Atorvastatin alone in nonconditioned media enhanced
tube formation in the Matrigel assay. However, the impact
of atorvastatin on endothelial cells and their function is
controversial. High concentrations of atorvastatin were
previously shown to inhibit HUVEC sprouting and growth
factor-induced proliferation in vitro [30]. In our experi-
ments, we used aortic endothelial cells and culture media
with reduced concentration of serum or even serum-free
media. Furthermore, we stimulated HAoEC with atorvastatin
only for a short period, suﬃcient to form tube-like structures
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on Matrigel, while Dulak et al. stimulated cells for 48 hours
[30]. Interestingly, 1 μmol/L atorvastatin enhanced VEGF
and IL8 promoter activities but decreased their production
by human microvascular endothelial cells in hypoxia [31].
Furthermore, Dang and coworkers showed that 10μmol/L
atorvastatin did not aﬀect tube formation by HUVEC in an
overnight stimulation [32]. Atorvastatin also decreased
endothelial senescence and dysfunction induced by angioten-
sin II [32]. On the other hand, atorvastatin administered
orally inhibited inﬂammatory angiogenesis and production
of VEGF in sponge transplants in mice [33]. When adminis-
tered in low dose (10mg/kg/day, orally) but not high dose
(30mg/kg/day), atorvastatin improved angiogenesis in ische-
mic limbs in the murine hind limb ischemia model [34]. It
also enhanced the expression of proangiogenic VEGF, IL-8,
and Hmox1 [34].
In HUVEC, atorvastatin increased heme oxygenase-1
mRNA but did not inﬂuence HMOX1 protein levels [30].
Levels of HMOX1 were also unaﬀected in human microvas-
cular endothelial cells (HMEC1) treated with a clinically rel-
evant concentration of atorvastatin (0.1μmol/L) [35]. In our
hands, we did not observe signiﬁcant changes in HMOX1
expression in PAC stimulated with 30μmol/L atorvastatin.
In vivo, in mouse lungs and hearts, atorvastatin (and
other statins) increased heme oxygenases’ activity and heme
oxygenase-1 but not 2 mRNA and protein levels [36]. In
other experimental settings, high doses of simvastatin and
lovastatin were able to increase heme oxygenase-1 levels in
HUVEC independently of NFκB and Nrf2 signalling [37].
Furthermore, Hmox1 was also upregulated by statins in
RAW264.7 macrophages, and p38 MAPK, ERK, and protein
kinase Gmediated its induction [23]. Therefore, we concluded
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that the impact of atorvastatin is most probably dependent
on the cell type.
Enhanced angiogenic properties of atorvastatin-
stimulated cells observed in vitro in the Matrigel tube forma-
tion assay were not conﬁrmed with the ﬁbrin bead assay
in vitro and in vivo Matrigel plug assay. However, in both
tests, the conditioned media were more diluted than in the
Matrigel tube formation assay. Interestingly, there was no
diﬀerence in the number of CD31+ cells in Matrigel plugs
implanted both peritoneally and subcutaneously in rats
administered orally with 15mg/kg/day of atorvastatin for
seven days [38]. However, the number of αSMA+ smooth
muscle cells was decreased in subcutaneous implants, which
may suggest the impact of atorvastatin on stability of newly
formed blood vessels [38].
Matrigel plugs with conditioned media were injected
subcutaneously to Foxn1nu mice, which are not able to pro-
duce T lymphocytes, but have relatively normal innate
immunity. One may speculate that the eﬀect of media on
angiogenesis could be hampered by inﬁltrating murine
immune cells, which comprised the majority of cells found
in plugs regardless of the type of media used (Figure 3(d)).
Importantly, conditioned media from CD34+-derived cells
stimulated with all compounds contained similar levels of
growth factors and inﬂammatory mediators. However, to
fully address the issue of the immune response to human
proteins or cells in the proposed experimental setting, we
would have to use humanised animals.
Finally, prolonged stimulation with atorvastatin tended
to increase levels of MCP-1, which can induce arteriogenesis
[39, 40]. However, in our study, we did not observe such an
eﬀect in vivo with ultrasound measurement of blood ﬂow
inside the plugs. Moreover, atorvastatin was shown previ-
ously to inhibit MCP-1 production in rabbit vascular smooth
muscle cells [41] and U937 monocytic cell line [42] and pos-
sibly aﬀecting the ﬁnal outcome in vivo.
To conclude, the eﬀects of atorvastatin on the para-
crine angiogenic activity of CD34+-derived cells could be
observed only in vitro and not in vivo. Levels of tested
cytokines and tested parameters of microvesicles in media
that enhanced angiogenesis were not changed. Therefore,
we believe that the eﬀect observed in vitro most probably
results rather from the orchestrated small changes in many
factors than a single one.
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